MetaCap

PepGen Inc. (PEPG)

NASDAQ: PEPGHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.78-0.15 (-3.82%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PEPG stock chart

Technical analysis

Key statistics

All statistics
Market cap
$356.31M
EPS (TTM)
-$0.77
52-week range
1.31 – 7.80
Day range
3.69 – 3.98
Volume / Avg
4.43M / 3.26M
Beta
—

52-week range

$1.31$7.80

PEPG stock today

On Nov 20, PEPG ended the session at $3.78, shedding $0.15 (3.82%), versus the S&P 500's 3.70% decline. At this level, PEPG sits in the middle of its 52-week range of $1.31 to $7.80: 51.5% below the high, set on Jan 2, 2026 and 188.5% above the low. PEPG is down 41.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 32.0%.

PepGen has posted a net loss over the last twelve months (EPS of -$0.77), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About PepGen

Company profile

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. James G. McArthur Ph.D.
Headquarters
Boston, MA
Employees
53
IPO year
2022
Website
pepgen.com

Financial highlights

Full financials

PepGen reported a net loss of $89.7 million, compared with a loss of $90.0 million a year earlier. Diluted earnings per share came in at -$2.12.

PepGen annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-89.66M$-89.98M$-78.63M$-69.10M$-27.28M
EPS (diluted)$-2.12$-2.85$-3.30$-4.42$-30.27

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$13.75+263.76%

  • Strong buy 0
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.28 vs $-0.27
Surprise
-3.70%

PEPG news

All PEPG news

PepGen peers

Health Care sector
PEPG peer companies
CompanyPrice% ChgMarket capCompare
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs PEPG
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs PEPG
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs PEPG
PHATPhathom Pharmaceuticals Inc.4.66-8.27%$378.82Mvs PEPG
MPLTMapLight Therapeutics Inc.5.94-7.48%$330.12Mvs PEPG
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs PEPG
LRMRLarimar Therapeutics Inc.3.14-2.48%$328.55Mvs PEPG
IRDOpus Genetics Inc.3.99-2.21%$385.65Mvs PEPG

Indexes, lists and sector

PepGen stock FAQ

What is PepGen's stock price today?

PEPG last traded at $3.78 as of Nov 20, 4:00 PM EST, down 3.82% on the day. Prices are delayed at least 15 minutes.

Who is PepGen's CEO?

Dr. James G. McArthur Ph.D. is the chief executive officer of PepGen Inc., which has about 53 employees.

What is the PEPG 52-week high?

The 52-week high for PEPG is $7.80 and the 52-week low is $1.31. The stock is currently 51.5% below its high.

Compare PEPG